Drugs / NPT520-34
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03954600 | May → Oct 2019 | — | Neuropore Therapies Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPT520-34 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03954600 ↗ |
| Route | Oral | “NPT520-34, 125 mg oral capsules (size 1)” NCT03954600 ↗ |